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ABSTRACT 
PREDICTED 25-HYDROXYVITAMIN D SCORE AND RISK OF MULTIPLE 
SCLEROSIS IN U.S. WOMEN 
 
MAY 2015 
 
ALEXANDRA C. PURDUE-SMITHE, B.S., UNIVERSITY OF MASSACHUSETTS 
AMHERST 
 
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Elizabeth Bertone-Johnson 
 
Multiple sclerosis (MS) is a progressive, autoimmune neurodegenerative disorder 
affecting nearly 350,000 people in the United States and resulting in significant disability. 
As an immunomodulator, vitamin D may play a role in the development of MS. Previous 
studies have observed an inverse association of 25-hydroxyvitamin D (25(OH)D) levels 
and MS risk in younger populations; however, whether this relationship persists in older 
adults remains unclear. We prospectively investigated the association between predicted 
25(OH)D level and incident MS in the Nurses’ Health Study (NHS) (n=121,701) and 
NHS II (n=116,430). 25(OH)D levels were predicted using validated regression models 
that include important determinants of vitamin D status, including race, UV-B flux (based 
on state of residence), physical activity, body mass index, dietary vitamin D intake, 
alcohol consumption and post-menopausal hormone use. Data on these factors were self-
reported on NHS and NHS II questionnaires starting in 1986 and 1991, respectively, and 
updated every 2-4 years. MS diagnoses were ascertained by self-report and confirmed by 
medical records. Cox proportional hazards models adjusted for age, ethnicity, latitude of 
residence at age 15, and BMI at age 18 were used to estimate hazard ratios (HR)s and 
95% confidence intervals (CI)s in each cohort. During up to 18 years of follow-up, we 
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documented 179 definite/probable cases of MS with first symptoms after baseline. 
Multivariable HRs comparing highest and lowest quintiles of predicted 25(OH)D were 
1.09 (95% CI: 0.40-2.96) in the NHS and 0.52 (95% CI: 0.28-0.95) in the NHS II. Higher 
predicted plasma 25(OH)D may be modestly associated with lower risk of MS, primarily 
in younger women.  	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 1 
CHAPTER 1 
 
 
INTRODUCTION 
 Multiple sclerosis (MS) is a neurodegenerative disorder currently affecting an 
estimated 350,000 people in the United States.1 The incidence of MS is relatively low 
among adolescents (0.43 per 1,000) and individuals older than 60 (2.88 per 1,000). 
Highest incidence occurs in individuals 35 to 39 years of age.2 The risk of developing MS 
is 1.5 to 2.53 times higher in women compared to men; the sex-specific incidence rate for 
women is estimated to be 5.3 per 1,000 compared to 2.3 per 1,000 in men.2 Additionally, 
risk of MS is also higher among white individuals compared to black individuals.4 
MS is an autoimmune disorder in which inflammation of the central nervous 
system causes progressive degradation of the myelin sheath.5 Two clinical courses of the 
disease have been identified. Approximately 85% of MS cases are considered to be 
relapsing-remitting MS (RRMS), characterized by an evolution of neurologic dysfunction 
over the course of days to weeks, which subsequently plateaus and resolves.5 These 
attacks are considered to be the inflammatory phase of the disease, which is followed by 
the secondary progressive stage (SPMS) 10-15 years after initial onset in about 50-60%5 
of patients. In the relapsing-remitting phase of MS, patients often experience ataxia, optic 
neuritis, muscle weakness and numbness as a result of inflammatory lesions affecting 
brain, optic nerve and spinal cord.5 As lesions accumulate over a series of relapses, 
degradation continues as the patient enters the secondary progressive stage, resulting in 
worsening and non-remitting leg weakness, dementia, ataxia and spasticity, along with 
other neurological symptoms.1,5 Roughly 10% of cases have primary progressive multiple 
sclerosis (PPMS), experiencing the degenerative phase from outset without an initial 
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relapsing-remitting inflammatory phase.5 The progression of MS results in substantial 
disability.6  
Established risk factors for MS include infection by Epstein-Barr virus, cigarette 
smoking, high body mass index at age 18 and genetic predisposition.3,7  There are several 
genes associated with increased risk of MS. The most prominent genetic risk factor for 
MS is the HLA-DRB1*1501 risk allele; in individuals of northern European descent, this 
haplotype confers a 3-fold risk in MS.8 Prior studies have found no evidence to suggest 
that micronutrients other than vitamin D are associated with MS.9 
 
Vitamin D Hypothesis 
 Vitamin D plays in an important physiologic role in calcium and blood pressure 
regulation, neurodevelopment and modulation of immune response.4 The primary form of 
vitamin D (colecalciferol) comes from both sun exposure and dietary sources including, 
but not limited to fatty fish, fortified foods such as milk, and supplements.4 Sunlight 
exposure provides significantly more vitamin D than dietary sources. For example, 20 
minutes of sun exposure during the summer months provides 10,000 IU of vitamin D 
compared to 400 IU from 1 serving of fatty fish.4 
 Ecologic studies have observed a latitude gradient of MS risk, with higher 
incidence rates occurring with increasing latitude.10 Data from such studies have given 
rise to the hypothesis that the gradient in incidence rates may be explained by differential 
sun exposure and therefore, vitamin D exposure.4   
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Vitamin D Metabolism 
 Cutaneous synthesis of vitamin D occurs as UVB radiation from sunlight reacts 
with 7-dehydrocholesterol in the skin, forming pre-vitamin D and then cholecalciferol.4 
Cutaneous and dietary cholecalciferol are hydroxylated in the liver to 25-hydroxyvitamin 
D and later converted to 1,25-dihydroxyvitamin D by the kidney and target tissues.11 
The action of circulating 1,25-dihydroxyvitamin D is mediated by the vitamin D 
receptor (VDR), which regulates the expression of vitamin D responsive genes.12 Because 
VDR expression has been observed in central nervous system tissue, it has been 
hypothesized that this may be a site of vitamin D activity.12   
Increasing circulating levels of 1,25-dihydroxyvitamin D may activate VDR in 
the central nervous system.11 Activation of VDR in immune cells and neurons causes a 
decrease in the inflammatory response of T-helper-1 cells and an increase in the anti-
inflammatory response of T-helper-2 cells.11 Considering that MS is an inflammatory 
immune reaction of the central nervous system, increased VDR activation due to 
increased circulating 1,25-dihydroxyvitamin D may modulate the regulatory function of 
T cells, thereby protecting an individual from inflammation of central nervous tissue. In 
clinical studies of MS patients, significant correlations between serum 25-
hydroxyvitamin D and activity of T cells have been reported.13,14 
 
Epidemiology of Vitamin D and Multiple Sclerosis 
 Six prior epidemiological studies have directly investigated the association of 
vitamin D (dietary9 or serum 25(OH)D15-19) and MS. Three of these studies were 
prospective9,15,16 (two nested case-control15,16) and three were case-control studies.17-19 Of 
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the retrospective case-control studies, two reported an inverse association17,18 of serum 
25(OH)D and MS, and one reported no association.19 While the results of two case-
control studies support an association of vitamin D and MS, the greatest limitation of the 
case-control study design is the collection of serum measurements after MS diagnosis. It 
is possible that lower vitamin D levels among cases are a consequence of MS, rather than 
an etiologic factor. Therefore, the primary way in which reverse causation can be 
eliminated in epidemiologic investigations is through prospective analyses.  
 In the best-designed study, Munger et al used a prospective, nested case-control 
study design to evaluate serum 25(OH)D level and risk of MS among 7 million U.S. 
service-men and -women whose blood samples and medical records make up the 
Department of Defense Serum Repository (DoDSR).15 The study used at least two serum 
25(OH)D measurements from blood samples drawn after entry into the military and prior 
to a probable/definite diagnosis of MS. In the analyses, 257 incident cases of MS were 
matched to 514 healthy controls according to age, sex, race/ethnicity, date of sample 
collection and branch of military service. The race-stratified results indicated a 
statistically significant inverse association for white men and women whose serum 
25(OH)D level fell into the highest quintile (OR=0.38; 95% CI: 0.19-0.75). Among 
blacks, serum 25 (OH)D in the highest tertile was not associated with MS (OR=1.05; 
95% CI: 0.51-2.17). Among Hispanics, the OR of serum 25(OH)D >100 nmol/L 
compared to serum 25(OH)D <75 nmol/L was not statistically significant (OR=0.61; 
95% CI: 0.13-2.93). This was the first study to use repeated 25(OH)D measurements to 
assess vitamin D status prior to MS diagnosis. 
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 In another prospective study conducted by Munger et al, dietary vitamin D intake 
was also found to be inversely associated with MS risk within the Nurses’ Health Study 
(NHS) (n=92,253) and Nurses’ Health Study II (NHS II) (n=95,310).9 Vitamin D was 
assessed using food frequency questionnaires (FFQ) administered every two years, from 
which total vitamin D intake and supplemental vitamin D was estimated. Multiple 
sclerosis cases (n=173) through the year 1998 were ascertained by self-report on biennial 
questionnaires and confirmed as a probable/definite diagnosis by a physician. In the 
NHS, total vitamin D intake in the highest quintile was inversely associated with risk of 
multiple sclerosis (RR=0.41; 95% CI: 0.18-0.94) as compared to the lowest quintile. In 
the NHS II, total vitamin D intake in the highest quintile was non-significantly inversely 
associated with risk of MS (RR=0.83; 95% CI:0.41-1.67). However, in both the NHS and 
NHS II, the trend across quintiles was not statistically significant (p-trend= 0.16 and p-
trend=0.13, respectively). One limitation of this study was that dietary intake of vitamin 
D alone may not the most reliable estimate of circulating, bioavailable vitamin D due to 
the substantial effect of sunlight on serum 25(OH)D levels.  
In order to assess the association of vitamin D and MS in the NHS and NHS II, 
we were interested in using a more comprehensive exposure assessment of vitamin D that 
incorporated other contributing factors of vitamin D status. Using the NHS and NHS II 
cohorts provided an excellent opportunity to investigate the association of vitamin D and 
MS in older women, which the Munger et al DoDSR study was not able to do. Our study 
was conducted in the same population as the dietary vitamin D study conducted by 
Munger et al; however, in our analyses, by using predicted 25(OH)D scores, we were 
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able to use a more comprehensive exposure assessment than dietary vitamin D intake 
alone.  
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CHAPTER 2 
METHODS 
Study Design 
 We prospectively assessed the association between predicted 25(OH)D score and 
risk of MS within the Nurses’ Health Study and Nurses’ Health Study II.  
Study Population 
The NHS was established in the United States in 1976, when 121,701 married, 
registered nurses ages 30-55 from 11 states responded to a mailed questionnaire 
regarding lifestyle habits, health behaviors and medical history. The NHS II includes 
116,430 female registered nurses ages 25-42 in the United States who responded to a 
similar initial questionnaire mailed in 1989.  Participants of both cohorts are mailed 
biennial follow-up questionnaires that assess disease risk factors, new disease diagnoses 
and significant medical events.  
 Participants of the NHS were recruited from the registry of the American Nurses’ 
Association according to the age and marital status eligibility criteria. Participants of the 
NHS were selected from the following 11 states: New York, California, Pennsylvania, 
Ohio, Massachusetts, New Jersey, Michigan, Texas, Florida, Connecticut, and Maryland, 
representing the states with the largest number of registrants. Participants of the NHS II 
were recruited from 14 state nursing boards and were eligible if they met the age criteria 
and were excluded if they did not provide a social security number or alternative contact 
person. Participants of the NHS II were selected from the following states: California, 
Connecticut, Indiana, Iowa, Kentucky, Massachusetts, Michigan, Missouri, New York, 
North Carolina, Ohio, Pennsylvania, South Carolina, and Texas.  
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For the present analysis, we excluded women who died prior to baseline or who 
were missing baseline exposure information. Additionally, we excluded women 
developing MS who were missing date of first symptoms or who experienced symptom 
onset prior to baseline. (Table 1) After exclusions, 74,914 individuals in the NHS and 
95,106 individuals in the NHS II were included in the main analyses and contributed 
26,223,875 and 22,658,634 person-months of follow-up, respectively. In this analysis, 39 
women in the NHS and 140 women in the NHS II became incident probable/definite MS 
cases during follow-up. 
 
Predicted 25-hydroxyvitamin D Scores 
Serum 25(OH)D measurement is considered the “gold standard” approach to 
assessing vitamin D status. However, it is highly variable by season of blood draw and 
recent sun exposure.20 Reproducibility of serum measurements is relatively high across 2-
3 year intervals, but decreases over longer time periods. In the NHS, the intra-class 
correlation coefficient (ICC) for plasma 25(OH)D measured 2-3 years apart is 0.72. 
However, over 10-11 years, the correlation coefficient drops to 0.5, reflecting decreasing 
reliability with increasing time.20 
Long-term vitamin D status may be a better predictor of chronic disease risk; 
however, the expense and difficulty of obtaining repeated measures of serum 25(OH)D in 
a large prospective cohort study often limits feasibility. Ideally, in a prospective study, 
we would collect samples and measure serum 25(OH)D for all participants over each 
follow-up cycle; however, this is unrealistic given budgetary and logistic constraints. 
While plasma 25(OH)D measurements are available for a small subset of participants in 
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the NHS and NHS II cohorts, only 57 cases provided a blood sample prior to MS 
diagnosis.  
Because of the limitations of using directly measured 25(OH)D levels to assess 
the association of vitamin D and MS risk, we have instead used predicted 25(OH)D level 
as the exposure assessment. The purpose of using predicted scores in lieu of serum 
measurements was two-fold. First, it enabled us to capture changes in predictors of 
vitamin D status over longer time periods prior to MS onset. Using predictors of serum 
25(OH)D as a proxy for actual serum measurements allowed us to look at a longer 
potentially relevant etiologic time period. Second, it allowed for increased sample size of 
eligible cases and greater power to assess a potential difference in the association of 
vitamin D and MS in older versus younger women. 
 
Development of Predicted 25-hydroxyvitamin D Scores 
For both the NHS and NHS II, Bertrand et al created predicted 25(OH)D scores 
based on correlates of vitamin D status measured from biennial follow-up 
questionnaires.20 The scores were derived using the following covariates: race (white, 
black, other), energy-adjusted vitamin D intake from food sources (≥ 400, 300-399, 200-
299, 100-199, <100 IU/d), vitamin D from supplements (≥ 400, 200-399, 1-199, 0 IU/d), 
UVB-flux based on latitude of state of residence (<113°, 113°, >113°), BMI (<22, 22-
24.9, 25-29.9, 30-34.9, >35 kg/m2), physical activity (quintiles), alcohol intake (0, 1-4.9, 
5-9.9, 10 g/day), and hormone use (pre-menopausal, post-menopausal/unknown PMH, 
post-menopausal/never PMH, post-menopausal/past PMH, post-menopausal/current 
PMH). Race was included as a predictor as a proxy for skin tone. Alcohol intake and 
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energy-adjusted vitamin D intake from food sources and supplements was estimated from 
food frequency questionnaires that asked participants to estimate their average frequency 
of consumption of specific foods over the preceding 12 months. UVB flux for state of 
residence was an estimated composite of average UVB radiation based on latitude, 
altitude and cloud cover. Physical activity in MET-hours/week was estimated from 
nurses’ responses to questions regarding activity frequency and intensity on follow-up 
questionnaires and was used as a proxy for time spent outdoors.  
For each cohort, these covariates, along with age, season of blood draw and 
laboratory batch, were regressed as a linear function to predict serum 25(OH)D in a 
“training sample” of nurses (NHS n=2,079; NHS II n=1,497) who had available blood 
and had served as controls for all previous and ongoing nested case-control studies of 
vitamin D within the cohorts. Covariate information from the questionnaire cycle closest 
to the date of blood draw was used in the prediction model building. The regression 
coefficients for each covariate in this model were used to quantify predicted scores for 
participants of each cohort. (Table 2) Season of blood draw was not included in the 
derived scores because it does not affect long-term within-person variation of serum 
25(OH)D.  
For the NHS, predicted scores for each cycle of follow-up were derived for all 
living participants beginning in 1986 (the first year of comprehensive physical activity 
measurement and estimate of UVB-flux). Dietary and supplemental vitamin D estimates 
from FFQs (assessed every four years) were carried forward from the previous FFQ for 
non-FFQ years. In the event that a participant had incomplete data on a predictor from a 
follow-up questionnaire, values from the previous cycle were carried forward one cycle 
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(with the exception of menopausal status/PMH use). UVB flux was not assessed in 2004; 
therefore, the value from 2002 was used. For participants who were missing data on a 
specific predictor for more than one follow-up cycle and for those who did not respond at 
all to the follow-up questionnaire during a cycle, a prediction score was not created and 
participants did not contribute to person-time in this cycle. 
For the NHS II, prediction scores were created similarly, using the same set of 
predictors assessed from biennial follow-up questionnaires. The first year of derivation 
was 1991; scores were derived for all women who responded to the 1991 questionnaire 
and FFQ and were derived for each questionnaire year thereafter through 2003. For 
questionnaire years 2005 and 2007, predicted scores from 2003 were carried forward. 
Missing data on individual predictors were carried forward, as described for the NHS 
cohort.  
 
Validity of the Prediction Model 
A separate, independent “test sample” of nurses in each cohort with available 
plasma 25(OH)D measurements from a more recent nested case-control study was used 
to validate the scores estimated by the “training sample” data set. Bertrand et al compared 
derived scores for the “test sample” that were estimated from the regression coefficients 
of the “training sample” model to actual plasma 25(OH)D measurements. 
The validity of the predicted 25(OH)D scores in the NHS and NHS II was 
evaluated by comparison to plasma 25(OH)D levels in the aforementioned “test sample” 
of participants of each cohort (NHS, n=818; NHS II, n=479).20 The Spearman correlation 
coefficients between predicted score and plasma 25-hydroxyvitamin D level adjusted for 
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season, batch, and age were 0.33 and 0.42 for the NHS and NHS II, respectively.20 For 
NHS, the prediction model explained 33% of the variability in plasma 25(OH)D. For 
NHS II, the prediction model explained 25% of serum 25(OH)D variability.20 
 
Assessment of Multiple Sclerosis 
 Documentation of incident MS cases in the NHS and NHS II was initiated by self-
report of new diagnosis on one of the biennial follow-up questionnaires. In the event that 
a nurse indicated a new diagnosis, she was asked permission by investigators to contact 
her treating physician or neurologist and review medical records. Upon obtaining 
permission, the physician or neurologist was sent a questionnaire, which addressed the 
following aspects of the diagnosis: certainty of diagnosis (definite, probable, possible, or 
not MS), date of symptom onset, laboratory test results, attack history, type of MS and 
other relevant information pertaining to the diagnosis. Diagnoses were classified as 
definite, probable, possible, or not MS according to Poser MS diagnostic criteria.21 
Definite cases were defined as clinically definite or laboratory-supported definite MS. 
Probable cases were defined as clinically probable or laboratory-supported probable MS. 
For the purposes of this analysis, we included only incident definite/probable MS cases in 
the main analyses. Cases were ascertained in two-year follow-up intervals.  
MS was first included as physician diagnosed condition on the 1992 (NHS) and 
1991 (NHS II) questionnaires. Since it is possible that MS may cause an individual to 
modify behaviors associated with the variables contributing to the 25(OH)D score, MS 
cases in the NHS who experienced symptom onset prior to the first available prediction 
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scores in 1986 and MS case in the NHS II who experienced symptom onset prior to 1991 
were excluded. 
Validity of Multiple Sclerosis Assessment 
 The validity of MS case ascertainment within the NHS and NHS II has been 
previously described by Hernan et al.21 Briefly, the medical records of a small sample of 
MS cases (n=39) were reviewed by study neurologists blinded to the diagnosis 
classification assigned by the nurses’ treating neurologist. Among probable/definite 
diagnoses from treating neurologists, classification with study neurologists was 
concordant 93% of the time. Therefore, diagnoses from the nurses’ treating neurologists 
were used in determining diagnosis classification for all MS cases. In the event that a 
nurse’s diagnosis from her treating neurologist was not available, the study neurologist 
made the diagnosis after a review of medical records.  
 
Covariate Assessment 
 Information regarding BMI, latitude of residence, and race was obtained from 
baseline questionnaires and were updated every two years from returned follow-up 
questionnaires. Because the aforementioned covariates were included in the prediction 
models for this exposure, to avoid over-adjustment, they were not included as covariates 
in the analyses. Instead, we adjusted for age9,15, cigarette smoking (pack-years)9, latitude 
of residence at age 15 (North: ≥41° latitude, Middle: 37-<41° latitude, South: <37° 
latitude)9, BMI at age 18 (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m2)3, and ethnicity (Southern 
European, Scandinavian, other Caucasian and other), based on inclusion in prior studies. 
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BMI at age 18, latitude of residence at age 15, and ethnicity was assessed at baseline 
(1976, NHS; 1989, NHS II). Smoking was updated for each follow-up cycle.  
 
Statistical Analysis 
First, we calculated general descriptive statistics of the distribution of predicted 
25(OH)D score in the NHS and NHS II. (Table 3) To evaluate confounders, we cross-
tabulated covariates by age-adjusted mean predicted 25(OH)D score at baseline (1986 
and 1991, respectively). (Table 4) Generalized linear models were used to assess age-
adjusted mean scores by covariates. Person-months were calculated from month of return 
of baseline questionnaire to month of MS symptom onset, death from any cause, or end 
of follow-up (2004 for NHS and 2009 for NHS II), whichever occurred first.  
Analyses were conducted separately for each cohort (NHS and NHS II). Cox 
proportional hazards models were used to evaluate the association between predicted 
25(OH)D score and MS, adjusting for covariates. To assess predicted 25(OH)D score and 
risk of MS, predicted scores were analyzed as a categorical variable (quintiles). Hazard 
ratios and 95% confidence intervals are reported. (Table 5) Mantel extension tests were 
used to assess trend across quintiles.  
A sensitivity analysis was conducted restricting to only definite MS cases. Age-
adjusted and multivariable Cox proportional hazards models were repeated excluding 
probable cases. Hazard ratios and associated 95% confidence intervals are reported. 
(Table 6)	  All analyses were conducted using SAS v9.3 (SAS Institute Inc, Cary, NC).  
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CHAPTER 3 
RESULTS 
 Table 3 shows the distribution of predicted scores in each cohort at baseline. 
Mean predicted 25(OH)D score was lower in the NHS than in the NHS II. In the NHS, 
scores in the lowest quintile ranged from 2.49 to 24.44, which was a greater range than 
any other quintile. The same was true in the NHS II; scores in the lowest quintile ranged 
from 14.48 to 28.55. The average age of symptom onset of cases was 54 years in the 
NHS and 45 years in the NHS II.  
 Because of high statistical power in this analysis, even small differences in the 
distribution of all covariates according to age-adjusted mean predicted 25(OH)D scores at 
baseline were statistically significant. (Table 4) In the NHS, women who were 55-59 
years old at baseline had the lowest mean predicted 25(OH)D score and women who 
were 45-49 years old at baseline had the highest mean predicted 25(OH)D score. Baseline 
mean 25(OH)D score was highest amongst women younger than 30, and lowest amongst 
women older than 45 in the NHS II. In both the NHS and NHS II, women of 
Scandinavian ethnicity had highest mean age-adjusted predicted score and women of 
“other” ethnicity had the lowest. Women who reported BMI at age 18 greater than 30 
kg/m2 had the lowest predicted age-adjusted mean score in both cohorts. In the NHS, 
women who had a middle latitude of residence at age 15 had the lowest age-adjusted 
mean predicted 25(OH)D score at baseline, while those who had a southern latitude of 
residence at age 15 had the highest. In the NHS II, age-adjusted mean 25(OH)D score 
was lowest for southern latitude of residence at age 15 and highest for northern latitude. 
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In both cohorts, age-adjusted mean 25(OH)D score was lowest for women who smoked 
greater than 25 packs per year.  
 Table 5 shows age-adjusted and multivariable-adjusted hazard ratios of MS by 
quintile of predicted 25(OH)D score. In the NHS, comparing Q5 vs. Q1 of predicted 
25(OH)D score was not associated with risk of MS (HR=1.15, 95% CI=0.42-3.12) (p-
trend=0.97). However, in the NHS II, women in the highest quintile (median=34.76) of 
predicted 25(OH)D had a significant lower risk of developing MS (HR=0.52, 95% 
CI=0.28-0.95), with some evidence of a linear trend (p-trend=0.07). 
 Table 6 shows age-adjusted and multivariable-adjusted hazard ratios of MS by 
predicted 25(OH)D score in analyses restricted to definite cases. In the NHS, results were 
somewhat stronger in analyses limited to definite cases, though our power for this 
comparison was low and the trend was not significant (p-trend=0.47). Women in the 
highest quintile of predicted score had a non-significant lower risk of MS (HR=0.58, 95% 
CI=0.13-2.57). In the NHS II, the inverse association was stronger when restricted to 
definite cases. For example, women in the highest quintile of predicted score experienced 
a 59% lower risk of developing MS as compared to those in the lowest quintile 
(HR=0.41, 95% CI=0.20-0.85). The linear trend was also significant (p-trend=0.04).  
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CHAPTER 4 
DISCUSSION 
 We observed an inverse association of predicted 25(OH)D score and risk of MS 
in the NHS II with some evidence of a dose-response relationship, although this 
association was not observed in the NHS. This difference may be due to variation in the 
association across age groups.   
 The findings of our study in the NHS II cohort are consistent with prior literature 
in younger adults. Although no prior studies have used a predicted 25(OH)D score as a 
proxy for vitamin D status, one prospective study of serum 25(OH)D and one prospective 
study of dietary vitamin D intake found a similar association. In a nested case-control 
study of U.S. service-men and –women, Munger et al reported a 62% lower risk of MS in 
white individuals in the highest quintile of serum 25(OH)D compared to those in the 
lowest quintile. In this population, the average age of MS onset was 28.5 years, which is 
closer to the age during follow-up of NHS II members than NHS members. For the NHS, 
the youngest possible age at start of follow-up in our study was later (40 years) compared 
to the NHS II (27 years). Earlier cases in the NHS were excluded because of the timing of 
the start of the prediction modeling in 1986, making this an older cohort during the 
exposure window than the NHS II. In the NHS, the average age of onset was 54, which 
may have contributed to the lack of association for this cohort.  
In a prospective study of dietary vitamin D intake in the NHS and NHS II, 
Munger et al found that total dietary vitamin D intake in the highest quintile was 
associated with a 59% decreased risk of MS in the NHS (RR=0.41; 95% CI: 0.18-0.94). 
In the NHS II, total dietary vitamin D intake in the highest quintile was associated with a 
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17% decreased risk of MS (RR=0.83; 95% CI: 0.41-1.67). In the NHS, among the four 
cases with supplemental vitamin D ≥ 400 IU/day, there was a 65% decreased risk of MS 
compared to non-supplement users with a non-significant trend (p-trend=0.10). In the 
NHS II, among the 14 cases with supplemental vitamin D ≥ 400 IU/day, there was 30% 
decreased risk of MS compared to non-supplement users and the trend was not significant 
(p-trend=0.18).   
One reason that Munger et al may have found a strong inverse association of 
dietary vitamin D intake and MS in the NHS cohort while our study did not may be due 
to the younger cases included in their analysis. By design, our study excluded all cases of 
MS that experienced symptom onset prior to 1986 (the first year of available predicted 
scores), meaning that the youngest possible age of MS cases included in our analysis was 
40. Their study included cases collected from 1980 to 1998, which means that the 
youngest possible cases included in their analysis was 34. This discrepancy in the age of 
cases may partially explain the strong inverse association of dietary vitamin D intake in 
the NHS that Munger et al found while we observed no association. The lack of 
association that we observed in the NHS (older women) and the strong inverse 
association that we observed in the NHS II (younger women) is consistent with the 
highest incidence rates occurring in younger women and lower incidence rates occurring 
with increasing age.  
In the NHS II, results from this study are consistent with ours; however, we 
observed an even stronger association than Munger et al and our results were statistically 
significant. The non-significant findings in the NHS II that Munger et al observed for 
dietary vitamin D intake may have been affected by non-differential misclassification of 
 19 
the exposure. Because vitamin D status is influenced by a variety of different factors 
(particularly sun exposure), dietary vitamin D intake may not be the most reliable of 
vitamin D status. In our study, by using predicted 25(OH)D scores as a proxy for vitamin 
D status rather than dietary vitamin D intake alone, other predictors of vitamin D status 
were incorporated into the exposure, reducing non-differential misclassification. This 
may explain the stronger results we observed in the NHS II compared the dietary vitamin 
intake study.  
Our study has several strengths. First, in prospective cohorts of 121,701 and 
116,430 women, there were 26,223,875 and 22,658,634 person-months of follow-up 
contributed in the NHS and NHS II, respectively. Follow-up for each questionnaire cycle 
is at least 89% and is even higher for prospective analyses and thus, selection bias due to 
differential follow-up in this study is unlikely. Another strength of our study is that we 
were able to censor MS cases at date of first symptoms. MS cases often experience first 
symptoms long before physician diagnosis. Symptoms of MS, which are exacerbated by 
heat, may have induced behavior change related to vitamin D exposure before date of 
diagnosis and thus, censoring at date of symptom onset rather than date of diagnosis 
reduces the potential for reverse causation. In our study, because predicted 25(OH)D 
scores are updated biennially, we were able to capture changes in exposure status 
throughout the duration of follow-up. By using the NHS and NHS II cohorts, we were 
able to assess the association of vitamin D status and risk of MS in older adult women 
using a proxy of vitamin D status, an association that has not previously been elucidated.  
Because repeated 25(OH)D measurements are not available for most cohorts, the 
use of predicted 25(OH)D scores as a proxy for blood measurements is a practical and 
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cost-effective way to assess the association between vitamin D and MS. Using predicted 
25(OH)D scores in lieu of serum measurements may best be viewed as a trade-off of 
strengths. By using updated predicted scores in prospective analyses as a proxy for serum 
measurements, we sacrificed direct measurements but gained the ability to prospectively 
assess vitamin D over a longer time period prior to MS onset. 
 There are also some limitations to our study. Predicted 25(OH)D scores were 
estimated from self-reported covariates including race, energy-adjusted vitamin D from 
food, vitamin D from supplements, BMI, physical activity, alcohol intake and hormone 
use.20 It is possible that women may have inaccurately reported some of these covariates, 
which may have caused participants to fall into inappropriate quintiles of predicted 
25(OH)D score. Several predictors of vitamin D status including skin tone, time spent 
outdoors, sunscreen use and genetic polymorphisms (i.e., VDR and VDBP expression) 
were not directly measured and incorporated in the derivation of predicted scores. 
However, race and physical activity were used as proxy measurements for skin tone and 
time spent outdoors, respectively, in an effort to include these factors.  
It is important to note that the Spearman correlation coefficients between 
predicted scores and serum measurements adjusted for age, batch, and season of blood 
draw for the NHS and NHS II are 0.33 and 0.40, respectively. Serum 25(OH)D has 
moderate within-person variability, and thus is not a true “gold standard” of vitamin D 
status. In the NHS, the intra-class correlation coefficient (ICC) for serum 25(OH)D over 
2-3 years is 0.7220, which indicates fairly high reproducibility. However, over 10-11 
years, the ICC is 0.5020, indicating decreasing reproducibility with increasing time. 
Fitting the predictors to a single serum 25-hydroxyvitamin D measurement likely 
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underestimated the correlation coefficients between serum values and predicted scores. 
According to Bertrand et al, in a comparison of quintiles of serum 25(OH)D and 
predicted 25(OH)D scores, 24.8% of NHS participants and 29.9% NHSII participants fell 
into identical quintiles. 59.8% of NHS participants and 66.5% of NHSII participants fell 
into the same or adjacent quintiles and only 5% or less of the participants fell into 
extreme opposite quintiles.20  
Misclassification of the exposure is likely and if present, caused a bias towards 
the null. The middle quintiles may have been particularly affected; however, comparison 
between extreme quintiles (i.e., low versus high score) is likely a more robust comparison 
because of the low rate of misclassification into extreme opposite quintiles. While the 
predicted scores do not directly measure vitamin D deficiency/sufficiency per se, their 
relative ranking of women into quintiles is likely to be generally accurate for extreme 
opposite ends of the spectrum. Women who fell into the lowest quintile of predicted 
25(OH)D score likely correspond to women who are truly vitamin D deficient and vice 
versa. Importantly, if misclassification of the exposure occurred, we would expect that 
the true association would be even stronger than we observed.  
It could be argued that null results in the NHS are the result of non-differential 
misclassification of exposure rather than a true lack of an association for older women. 
However, the difference in Spearman correlation coefficients of serum 25(OH)D and 
predicted score between the NHS (r=0.33) and NHS II (r=0.40) is relatively small, and is 
unlikely to explain a null association in the NHS considering such a strong inverse 
association in the NHS II. It is unlikely that the NHS experienced a much higher degree 
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of non-differential misclassification of exposure than the NHS II, and thus, we attribute 
the difference in results to a potential variation in the association across age groups.  
 For the NHS and NHS II, the covariates used to create the prediction scores 
accounted for 33% and 25% of the variability in serum 25(OH)D.20 The remaining 
unexplained variability can likely be attributed to measurement error of predictor 
variables and missing information regarding other determinants of vitamin D status, such 
as genetic factors.20 We do not have available information regarding infection of Epstein-
Barr virus (a known risk factor for MS) for the entire NHS and NHS II cohorts; however, 
this is unlikely to confound the association between predicted 25(OH)D score and MS. 
While EBV infection is associated with risk of MS, it is not associated with serum 
25(OH)D.7 Additionally, genes associated with increased risk of MS such as HLA-
DRB1*1501, have not been associated with serum 25(OH)D levels.8 Essentially, some of 
the remaining variability of serum 25(OH)D unexplained by the covariates of the 
prediction scores is likely to be related to genetic factors affecting plasma 25(OH)D, but 
these same genetic factors have not been consistently associated with risk of MS.4 
Because of this, we expect the effect of confounding by genetic factors to be relatively 
small. Other dietary components may interact with vitamin D; however, other vitamins 
and minerals have not been consistently associated with risk of MS.9 Therefore, we also 
expect the effect of confounding by other dietary factors to be relatively small.  
 The results of this study are generalizable to other women of similar age in the 
United States. The association of predicted 25(OH)D score and MS may differ in 
adolescents and thus, findings may not be generalizable to this group.  
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CHAPTER 5 
CONCLUSION 
In conclusion, the results of our study expand upon the existing literature that 
supports a protective role of vitamin D on risk of MS. Our analyses suggest that predicted 
25(OH)D score, as a proxy for vitamin D status, is associated with lower risk of MS in 
younger women; however, this association was not observed in older women.  
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TABLES 	  
Table 1. Exclusion criteria: Nurses’ Health Study & Nurses’ Health Study II 
   NHS NHSII 
 
 N N 
Original study sample 121,701 116,430 
Missing date of first symptoms 14 45 
MS onset prior to first score derivation  127 111 
Death prior to baseline 2293 5 
Missing baseline prediction scores 43193 21163 
   Final study sample 75,914 95,106 
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Table 2. Predictors of serum 25-hydroxyvitamin D from multivariable linear regression 
models in the Nurses’ Health Study & Nurses’ Health Study II 
Predictor NHS P NHSII P  
 
n=2079 
 
n=1497 
 
 
Difference 
in 25(OH)D 
(ng/ml; β)  
 
Difference 
in 25(OH)D 
(ng/ml; β)  
 Intercept 22.69 
 
35.78 
 Age (years) 0.07 0.07 −0.23 <0.0001 
Race 
 
<0.001 
 
<0.001 
White  0 
 
0 
 Black  −11.3 
 
−6.42 
 Asian − 
 
−5.55 
 Hispanic − 
 
−6.83 
 Other −1.63 
 
1.98 
 UV-B flux category 
 
<0.0001 
 
0.67 
1 (highest) 0 
 
0 
 2 −2.69 
 
−0.16 
 3 −1.29 
 
−0.66 
 4 − 
 
−0.6 
 5 (lowest) − 
 
− 
 Dietary vitamin D (µg/d) 
 
<0.0001 
 
0.003 
<2.5 0 
 
0 
 2.5- <5 0.92 
 
1.56 
 5- <7.5 2.19 
 
1.87 
 7.5- <10 3.43 
 
3.55 
 ≥10 3.33 
 
2.49 
 Supplementary vitamin D 
(µg/d) 
 
<0.0001 
 
<0.001 
0 0 
 
0 
 0.025- <5 2.85 
 
0.76 
 5- <10 1.57 
 
2.05 
 ≥10 3.15 
 
2.7 
 BMI (kg/m2) 
 
<0.0001 
 
<0.0001 
< 19  − 
 
2.22 
 < 22 (19-21.9 in NHS II) 0 
 
0 
 22-24.9 −0.57 
 
−0.38 
 25-29.9 −1.95 
 
−2.35 
 30-34.9 −3.32 
 
−5.09 
 ≥ 35 −8.16 
 
−6.17 
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Predictor NHS P NHSII P  
 
Quintile of physical activity 
 
<0.0001 
 
<0.0001 
1 (lowest) 0 
 
0 
 2 1.77 
 
0.99 
 3 1.15 
 
1.2 
 4 2.13 
 
3.07 
 5 (highest) 3.66 
 
3.79 
 Post-menopausal hormone use 
 
<0.001 
 
0.12 
1 0 
 
0 
 2 −1.66 
 
0.17 
 3 −2.11 
 
1.94 
 4 −1.17 
 
1.53 
 5 −0.66 
 
0.71 
 Alcohol intake (g/d) 
 
<0.0001 
 
<0.001 
0 0 
 
0 
 > 0- <5 0.24 
 
1.34 
 5- <10 1.33 
 
2.38 
 ≥10 2.62 
 
2.69 
 Season of blood draw 
 
<0.0001 
 
<0.0001 
Autumn 0 
 
0 
 Summer 1.18 
 
1.33 
 Spring −2.68 
 
−5.55 
 Winter −3.35 
 
−5.61 
 *Table adapted from Bertrand et al20 
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Table 3. Distribution of predicted 25-hydroxyvitamin D scores at baseline: Nurses’ 
Health Study & Nurses’ Health Study II 
 
N M (SE) Range  Median 
     NHS 
    Predicted 25-
hydroxyvitamin D 
score 75914    27.30 (0.01)         37.12 27.49 
     Predicted 25-
hydroxyvitamin D 
score  
    Q1 15172 21.60 (0.02)  21.95 22.60 
Q2 15106 25.57 (0.01) 2.14 25.59 
Q3 15240 27.50 (0.004) 1.84 27.49 
Q4 15174 29.39 (0.005)  2.02 29.36 
Q5 15222 32.40 (0.01) 9.13 32.00 
     NHS II 
    Predicted 25-
hydroxyvitamin D 
score 95106 31.20 (0.01) 26 31.64 
     Predicted 25-
hydroxyvitamin D 
score      
  Q1 19013 25.92 (0.02) 14.07 26.45 
Q2 18997 29.80 (0.005) 2.26 29.88 
Q3 19029 31.64 (0.003) 1.61 31.64 
Q4 19045 33.23 (0.004) 1.68 33.22 
Q5 19022 35.42 (0.007) 6.38 35.19 
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Table 4. Distribution of covariates according to age-adjusted mean 25-hydroxyvitamin D 
score at baseline: Nurses’ Health Study (1989) & Nurses’ Health Study II (1991) 
Covariate NHS NHS II 
 
Mean 25(OH)D Score (SE) Mean 25(OH)D Score (SE) 
Ethnicity 
  S. European 27.17 (0.04) 31.37 (0.03) 
Scandinavian 28.42 (0.07) 31.81 (0.05) 
Other caucasian 27.68 (0.02) 31.47 (0.01) 
Other 26.18 (0.03) 27.57 (0.04) 
   BMI at age 18  
  <18.5 27.98 (0.04) 32.24 (0.03) 
18.5-24.9 27.52 (0.02) 31.42 (0.01) 
25-29.9 25.26 (0.05) 28.61 (0.04) 
>=30 23.69 (0.07) 26.99 (0.07) 
   Latitude of residence at 
age 15 
  North  27.79 (0.02) 31.32 (0.02) 
Middle  26.80 (0.02) 31.29 (0.02) 
South 28.46 (0.05) 31.18 (0.03) 
   Smoking (pack-years) 
   Never 27.26 (0.12) 31.09 (0.01) 
<10 27.67 (0.03) 31.76 (0.03) 
 10-24 27.61 (0.04) 31.24 (0.03) 
 25+ 27.13 (0.02) 30.52 (0.06) 
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Table 5.  Age-adjusted and multivariate HR and 95% CI of multiple sclerosis by quintile 
of predicted 25-hydroxyvitamin D score: Nurses’ Health Study & Nurses’ Health Study 
II 
 
Person-months      Age-adjusted  Multivariate* P-trend 
 
Cases (N) HR (95% CI) HR (95% CI) 
 
     NHS 26,223,875 
  
P=0.97 
 
N=39  
   Q1 
 
1.0 (Referent) 1.0 (Referent) 
 
     Q2 
 
1.24 (0.49-3.13) 1.27 (0.49-3.27) 
 
     Q3 
 
0.49 (0.15-1.63) 0.49 (0.14-1.65) 
 
     Q4 
 
0.99 (0.37-2.64) 0.97 (0.35-2.67) 
 
     Q5 
 
1.13 (0.45-3.01) 1.15 (0.42-3.12) 
 
     NHS II 22,658,634 
   
 
N=140 
   Q1 
 
1.0 (Referent) 1.0 (Referent) P=0.07 
     Q2 
 
0.79 (0.48-1.28) 0.81 (0.49-1.35) 
 
     Q3 
 
0.71(0.43-1.17) 0.74 (0.43-1.26) 
 
     Q4 
 
0.82 (0.51-1.33) 0.87 (0.51-1.46) 
 
     Q5 
 
0.49 (0.28-0.87) 0.52 (0.28-0.95) 
 
     *Adjusted for age, ethnicity, latitude of residence at age 15, BMI at age 18 and smoking 
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Table 6. Age-adjusted and multivariate HR and 95% CI of multiple sclerosis by 
predicted 25-hydroxyvitamin D score restricted to definite cases: Nurses’ Health Study & 
Nurses’ Health Study II 
 
Person-months      Age-adjusted  Multivariate* P-trend 
 
Cases (N) HR (95% CI) HR (95% CI) 
 
     NHS 26,223,875 
   
 
N=20 
   Predicted 25(OH)D  
   
P=0.47 
Q1 
 
1.0 (Referent) 1.0 (Referent) 
 
     Q2 
 
0.98 (0.28-3.38) 1.00 (0.28-3.55) 
 
     Q3 
 
0.39 (0.08-2.00) 0.37 (0.07-2.00) 
 
     Q4 
 
0.98 (0.28-3.40) 0.92 (0.25-3.36) 
 
     Q5 
 
0.63 (0.15-2.63) 0.58 (0.13-2.57) 
 
     NHS II 22,658,634 
   
 
N=102 
   Predicted 25(OH)D  
   
P=0.04 
Q1 
 
1.0 (Referent) 1.0 (Referent) 
 
     Q2 
 
0.69 (0.39-1.22) 0.71 (0.39-1.29) 
 
     Q3 
 
0.73 (0.41-1.27) 0.76 (0.42-1.39) 
 
     Q4 
 
0.73 (0.42-1.28) 0.77 (0.42-1.42) 
 
     Q5 
 
0.38 (0.19-0.77) 0.41 (0.20-0.85) 
 
     *Adjusted for age, ethnicity, latitude of residence at age 15, BMI at age 18 and smoking 
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